In relapsed acute lymphoblastic leukemia (ALL), H3K36me3, a substrate of KDM4A, localizes components of the DNA damage response (DDR) pathway and induces resistance to DNA damage agents (doxorubicin, etoposide, 6-thioguanine, and cytarabine), while KDM4A inhibition could restore the H3K36me3 level and sensitize ALL cells to cytarabine.53 This evidence concerns the gene KDM4A and acute lymphoblastic leukemia.